Literature DB >> 16219029

In vivo interaction between serotonin and galanin receptors types 1 and 2 in the dorsal raphe: implication for limbic seizures.

Andrey M Mazarati1, Roger A Baldwin, Steve Shinmei, Raman Sankar.   

Abstract

The neuropeptide galanin suppresses seizure activity in the hippocampus by inhibiting glutamatergic neurotransmission. Galanin may also modulate limbic seizures through interaction with other neurotransmitters in neuronal populations that project to the hippocampus. We examined the role of galanin receptors types 1 and 2 in the dorsal raphe (DR) in the regulation of serotonergic transmission and limbic seizures. Infusion of a mixed agonist of galanin receptors types 1 and 2 [galanin (1-29)] into the DR augmented the severity of limbic seizures in both rats and wild-type mice and concurrently reduced serotonin concentration in the DR and hippocampus as measured by immunofluorescence or HPLC. In contrast, injection of the galanin receptor type 2 agonist galanin (2-11) mitigated the severity of seizures in both species and increased serotonin concentration in both areas. Injection of both galanin fragments into the DR of galanin receptor type 1 knockout mice exerted anticonvulsant effects. Both the proconvulsant activity of galanin (1-29) and seizure suppression by galanin (2-11) were abolished in serotonin-depleted animals. Our data indicate that, in the DR, galanin receptors types 1 and 2 modulate serotonergic transmission in a negative and a positive fashion, respectively, and that these effects translate into either facilitation or inhibition of limbic seizures.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16219029      PMCID: PMC1343489          DOI: 10.1111/j.1471-4159.2005.03498.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  41 in total

Review 1.  Galanin in ascending systems. Focus on coexistence with 5-hydroxytryptamine and noradrenaline.

Authors:  T Hökfelt; Z Q Xu; T J Shi; K Holmberg; X Zhang
Journal:  Ann N Y Acad Sci       Date:  1998-12-21       Impact factor: 5.691

2.  Differential intracellular signaling of the GalR1 and GalR2 galanin receptor subtypes.

Authors:  S Wang; T Hashemi; S Fried; A L Clemmons; B E Hawes
Journal:  Biochemistry       Date:  1998-05-12       Impact factor: 3.162

Review 3.  Mood disorders in patients with epilepsy: epidemiology and management.

Authors:  Cynthia L Harden; Martin A Goldstein
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

4.  Receptor subtype-specific pronociceptive and analgesic actions of galanin in the spinal cord: selective actions via GalR1 and GalR2 receptors.

Authors:  H X Liu; P Brumovsky; R Schmidt; W Brown; K Payza; L Hodzic; C Pou; C Godbout; T Hökfelt
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-31       Impact factor: 11.205

5.  Galanin/GMAP- and NPY-like immunoreactivities in locus coeruleus and noradrenergic nerve terminals in the hippocampal formation and cortex with notes on the galanin-R1 and -R2 receptors.

Authors:  Z Q Xu; T J Shi; T Hökfelt
Journal:  J Comp Neurol       Date:  1998-03-09       Impact factor: 3.215

Review 6.  Regulation of limbic status epilepticus by hippocampal galanin type 1 and type 2 receptors.

Authors:  Andrey Mazarati; Xiaoying Lu
Journal:  Neuropeptides       Date:  2005-01-28       Impact factor: 3.286

Review 7.  Initial treatment of epilepsy with antiepileptic drugs: pediatric issues.

Authors:  Raman Sankar
Journal:  Neurology       Date:  2004-11-23       Impact factor: 9.910

8.  Galanin modulation of seizures and seizure modulation of hippocampal galanin in animal models of status epilepticus.

Authors:  A M Mazarati; H Liu; U Soomets; R Sankar; D Shin; H Katsumori; U Langel; C G Wasterlain
Journal:  J Neurosci       Date:  1998-12-01       Impact factor: 6.167

9.  Patterns of seizures, hippocampal injury and neurogenesis in three models of status epilepticus in galanin receptor type 1 (GalR1) knockout mice.

Authors:  A Mazarati; X Lu; S Shinmei; H Badie-Mahdavi; T Bartfai
Journal:  Neuroscience       Date:  2004       Impact factor: 3.590

10.  Coexistence of galanin-like immunoreactivity with catecholamines, 5-hydroxytryptamine, GABA and neuropeptides in the rat CNS.

Authors:  T Melander; T Hökfelt; A Rökaeus; A C Cuello; W H Oertel; A Verhofstad; M Goldstein
Journal:  J Neurosci       Date:  1986-12       Impact factor: 6.167

View more
  19 in total

1.  Biological impact of low dose-rate simulated solar particle event radiation in vivo.

Authors:  P Y Chang; R Doppalapudi; J Bakke; A Wang; S Menda; Z Davis
Journal:  Radiat Environ Biophys       Date:  2010-05-16       Impact factor: 1.925

2.  Cell and gene therapies for refractory epilepsy.

Authors:  Detlev Boison
Journal:  Curr Neuropharmacol       Date:  2007       Impact factor: 7.363

3.  Plasticity of presynaptic and postsynaptic serotonin 1A receptors in an animal model of epilepsy-associated depression.

Authors:  Eduardo A Pineda; Julie G Hensler; Raman Sankar; Don Shin; Teresa F Burke; Andréy M Mazarati
Journal:  Neuropsychopharmacology       Date:  2011-02-23       Impact factor: 7.853

4.  Galanin contributes to monoaminergic dysfunction and to dependent neurobehavioral comorbidities of epilepsy.

Authors:  Jesus-Servando Medel-Matus; Don Shin; Raman Sankar; Andrey Mazarati
Journal:  Exp Neurol       Date:  2016-12-22       Impact factor: 5.330

Review 5.  Biomarkers of epileptogenesis: psychiatric comorbidities (?).

Authors:  Andres M Kanner; Andrey Mazarati; Matthias Koepp
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

6.  Hypoxic-ischemic brain injury exacerbates neuronal apoptosis and precipitates spontaneous seizures in glucose transporter isoform 3 heterozygous null mice.

Authors:  Camille Fung; Edward Evans; Don Shin; Bo-Chul Shin; Yuanzi Zhao; Raman Sankar; Gautam Chaudhuri; Sherin U Devaskar
Journal:  J Neurosci Res       Date:  2010-11-15       Impact factor: 4.164

Review 7.  Galanin receptor antagonists : a potential novel pharmacological treatment for mood disorders.

Authors:  Sven Ove Ogren; Eugenia Kuteeva; Tomas Hökfelt; Jan Kehr
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

8.  Effects of selective serotonin and norepinephrine reuptake inhibitors on depressive- and impulsive-like behaviors and on monoamine transmission in experimental temporal lobe epilepsy.

Authors:  Udaya Kumar; Jesus-Servando Medel-Matus; Hannah M Redwine; Don Shin; Julie G Hensler; Raman Sankar; Andrey Mazarati
Journal:  Epilepsia       Date:  2016-01-27       Impact factor: 5.864

9.  Phenotypic analysis of GalR2 knockout mice in anxiety- and depression-related behavioral tests.

Authors:  Xiaoying Lu; Brendon Ross; Manuel Sanchez-Alavez; Eric P Zorrilla; Tamas Bartfai
Journal:  Neuropeptides       Date:  2008-06-12       Impact factor: 3.286

10.  Depression after status epilepticus: behavioural and biochemical deficits and effects of fluoxetine.

Authors:  Andréy Mazarati; Prabha Siddarth; Roger A Baldwin; Don Shin; Rochelle Caplan; Raman Sankar
Journal:  Brain       Date:  2008-06-17       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.